Faramarz Valafar

Prof. Dr. Faramarz Valafar

Laboratory for Pathogenesis of Clinical Drug Resistance and Persistence, School of Public Health, San Diego State University, San Diego, CA, USA

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2002 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
FVFaramarz Valafar
Faramarz Valafar

8 July 2008 in PLOS Biology
Verified
Journal Article
Open access
PDF file
JHJon W Huss
Jon W Huss
COCamilo Orozco
Camilo Orozco
JGJames Goodale
James Goodale
CWChunlei Wu
Chunlei Wu
SBSerge Batalov
Serge Batalov
ASAndrew I Su
Andrew I Su
This manuscript describes the creation of comprehensive gene wiki, seeded with data from public domain sources, which will enable and encourage community annotation of gene function.

1 September 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SRSarah M. Ramirez-Busby
Sarah M. Ramirez-Busby
FVFaramarz Valafar
Faramarz Valafar
Pyrazinamide (PZA) is an important first-line drug in the treatment of tuberculosis (TB) and of significant interest to the HIV-infected community due to the prevalence of TB-HIV coinfection in some regions of the world. The mechanism of resistance to PZA is unlike that of any other anti-TB drug. The genepncA, encoding pyrazinamidase (PZase), is associated with resistance to PZA. However, because single mutations in PZase have a low prevalence, the individual sensitivities are low. Hundreds of distinct mutations in the enzyme have been associated with resistance, while some only appear in susceptible isolates. This makes interpretation of molecular testing difficult and often leads to the simplification that any PZase mutation causes resistance. This systematic review reports a comprehensive global list of mutations observed in PZase and its promoter region in clinical strains, their phenotypic association, their global frequencies and diversity, the method of phenotypic determination, their MIC values when given, and the method of MIC determination and assesses the strength of the association between mutations and phenotypic resistance to PZA. In this systematic review, we report global statistics for 641 mutations in 171 (of 187) codons from 2,760 resistant strains and 96 mutations from 3,329 susceptible strains reported in 61 studies. For diagnostics, individual mutations (or any subset) were not sufficiently sensitive. Assuming similar error profiles of the 5 phenotyping platforms included in this study, the entire enzyme and its promoter provide a combined estimated sensitivity of 83%. This review highlights the need for identification of an alternative mechanism(s) of resistance, at least for the unexplained 17% of cases.

7 December 2011 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
JRJason Rudy
Jason Rudy
FVFaramarz Valafar
Faramarz Valafar
Simultaneous measurement of gene expression on a genomic scale can be accomplished using microarray technology or by sequencing based methods. Researchers who perform high throughput gene expression assays often deposit their data in public databases, but heterogeneity of measurement platforms leads to challenges for the combination and comparison of data sets. Researchers wishing to perform cross platform normalization face two major obstacles. First, a choice must be made about which method or methods to employ. Nine are currently available, and no rigorous comparison exists. Second, software for the selected method must be obtained and incorporated into a data analysis workflow.

1 January 2015 in Emerging Microbes & Infections
Verified
Journal Article
Open access
JTJessica N Torres
Jessica N Torres
LPLynthia V Paul
Lynthia V Paul
TRTimothy C Rodwell
Timothy C Rodwell
TVThomas C Victor
Thomas C Victor
AAAnu M Amallraja
Anu M Amallraja
FVFaramarz Valafar
Faramarz Valafar
We report the discovery and confirmation of 23 novel mutations with previously undocumented role in isoniazid (INH) drug resistance, in catalase-peroxidase (katG) gene of Mycobacterium tuberculosis...

1 October 2011 in Vaccine
Verified
Journal Article
Closed access
BBBrett N. Bowman
Brett N. Bowman
PMPaul R. McAdam
Paul R. McAdam
Sandro VivonaSandro Vivona
Sandro Vivona
JZJin X. Zhang
Jin X. Zhang
TLTiffany Luong
Tiffany Luong
CWChristopher H. Woelk
Christopher H. Woelk